ML
MVM Life Science Partners
Venture CapitalActiveMVM Life Science Partners is a venture capital firm specializing in investments in start-up, early stage, mid venture, late venture.
55
Investments
8
Exits
$1.2B
AUM
14.5%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for MVM Life Science Partners.
Investment Thesis & Strategy
MVM Life Science Partners invests in life science companies across various stages, from startup to late venture, with a focus on early-stage and mid-venture opportunities.
Investment Activity
Deals per year over the last 7 years
1
20145
20151
20161
20171
20182
20191
2020Portfolio Companies
Selected investments from their portfolio of 55 companies
V
Ventyx Biosciences
Biotech · Series B, 2020
P
Prometheus Biosciences
Biotech · Series B, 2019
X
Xilio Therapeutics
Biotech · Series B, 2019
i
iTeos Therapeutics
Biotech · Series B, 2018
O
Obsidian Therapeutics
Biotech · Series B, 2017
I
Inari Medical
Healthcare · Series C+, 2016
S
Surface Oncology
Biotech · Series B, 2015
A
Aptinyx
Biotech · Series B, 2015
V
Voyager Therapeutics
Biotech · Series B, 2015
R
Revolution Medicines
Biotech · Series B, 2015
O
ObsEva
Biotech · Series C+, 2015
C
Cidara Therapeutics
Biotech · Series B, 2014
Notable Exits
CompanyTypeYearValue / Acquirer
Obsidian TherapeuticsIPO2024—
Ablaze PharmaceuticalsAcquisition2024—
AM PharmaAcquisition2023—
InCarda TherapeuticsAcquisition2023—
iTeos TherapeuticsIPO2021—
Audentes TherapeuticsAcquisition2019$3B
ObsEvaIPO2017—
AffimedIPO2014—
Frequently Asked Questions
MVM Life Science Partners focuses on Series A, Series B, Series C+ stage investments.